Verbeke, Rein

mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability

Schoenmaker, L., Witzigmann, D., Kulkarni, J. A., Verbeke, R., Kersten, G., Jiskoot, W., & Crommelin, D. J. A. (2021) · International Journal of Pharmaceutics

RNA Interference and Gene DeliveryNanoparticle-Based Drug Delivery

Cited by 1,566

The dawn of mRNA vaccines: the COVID-19 case

Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2021) · Journal of Controlled Release

SARS-CoV-2 and COVID-19 ResearchRNA Interference and Gene Delivery

Cited by 504

Three decades of messenger RNA vaccine development

Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2019) · Nano Today

Immunotherapy and Immune ResponsesRNA Interference and Gene Delivery

Cited by 342

Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message across

Minnaert, A.-K., Vanluchene, H., Verbeke, R., Lentacker, I., De Smedt, S. C., Raemdonck, K., Sanders, N. N., & Remaut, K. (2021) · Advanced Drug Delivery Reviews

RNA Interference and Gene DeliveryImmunotherapy and Immune Responses

Cited by 157

Co-delivery of nucleoside-modified mRNA and TLR agonists for cancer immunotherapy: restoring the immunogenicity of immunosilent mRNA

Verbeke, R., Lentacker, I., Wayteck, L., Breckpot, K., Van Bockstal, M., Descamps, B., Vanhove, C., De Smedt, S. C., & Dewitte, H. (2017) · Journal of Controlled Release

Immunotherapy and Immune ResponsesRNA Interference and Gene Delivery

Cited by 132

Particle-mediated intravenous delivery of antigen mRNA results in strong antigen-specific T-cell responses despite the induction of type I interferon

Broos, K., Van der Jeught, K., Puttemans, J., Goyvaerts, C., Heirman, C., Dewitte, H., Verbeke, R., Lentacker, I., Thielemans, K., & Breckpot, K. (2016) · Molecular Therapy — Nucleic Acids

RNA Interference and Gene DeliveryImmunotherapy and Immune Responses

Cited by 121